On May 15, 2025, Lyell Immunopharma held its annual stockholder meeting where 71.9% of shares were represented. Key votes included electing a director, approving Ernst & Young as auditors, and a proposal for a reverse stock split ranging from 1-for-10 to 1-for-25.